Blood Biomarkers and Mobility/Cognitive Impairment
Author Information
Author(s): Windham B Gwen, Blackshear Chad, Sullivan Kevin, Pike James, Walker Keenan, Mosley Thomas, Palta Priya, Griswold Michael
Primary Institution: University of Mississippi Medical Center
Hypothesis
Blood biomarkers of Alzheimer Disease pathology and neurodegeneration may identify individuals at risk for mobility and cognitive impairment.
Conclusion
Higher levels of certain blood biomarkers are associated with a greater prevalence of mobility and cognitive impairments in older adults.
Supporting Evidence
- Higher biomarkers were associated with greater prevalence of mobility, cognitive, and dual impairments.
- Incident impairments occurred in mobility-only, cognitive-only, and dual domains.
- P-tau181, -Aβ42|40, and GFAP were associated with incident cognitive-only impairment.
- P-tau181, NFL and GFAP were associated with incident mobility-only impairment.
Takeaway
Scientists studied blood tests to see if they could tell if older people might have trouble walking or thinking. They found that certain blood markers can help predict these problems.
Methodology
Multinomial regression models were used to examine the association between blood biomarkers and mobility/cognitive impairments over time.
Participant Demographics
Mean age 76.2 years, 41% men, 28% Black.
Statistical Information
Confidence Interval
95% CI: 1.45, 4.44
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website